SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

This study is an open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with immunotherapy in the recurrent or metastatic head and neck squamous cell carcinoma.

Trial Details

NCT ID
NCT07254585
Phase
PHASE2
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • SYS6010 injection
  • Enlonstobart injection
  • Pembrolizumab injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged 18-75 (inclusive) years old, male or females;
  • Participants with histologically confirmed recurrent or metastatic head and neck squamous cell carcinoma who are not suitable for radical surgery o…
  • For SYS6010 combined with Enlonstobart group or SYS6010 combined with Pembrolizumab group : Participants who have not previously received systemic …
  • For Enlonstobart group: Participants who have not previously received immunotherapy are included. For participants who have not previously undergon…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →